Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs
International Journal of Molecular Sciences · 14.08.2026 · 27 (16) · 7260
DOI: 10.3390/ijms27167260 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.08.2026. Verfasst von Katarina Resen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Germ-Line Mutation, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Germline EGFR pathogenic variants (PVs) are rare and define a distinct hereditary subset of NSCLC with unique clinical characteristics. Germline EGFR p.T790M is the most frequent and best characterized, with reported sensitivity to first- and second-generation EGFR-TKIs. Yet, the response of germline EGFR variants, especially the rarer ones such as p.V843I, to osimertinib remains poorly characterized. Given the very low frequency of germline non-p.T790M variants, their clinical relevance can only be investigated via case reports. Herein, we report what is, to the best of our knowledge, the first case of advanced lung adenocarcinoma harboring a germline EGFR p.V843I variant coexisting in cis with the unusual somatic EGFR exon 19 C-helix deletion, p.S752_I759del. Additionally, a somatic TP53 variant was detected. Treatment with afatinib induced a partial response lasting only six months, as rapid disease progression occurred without identifiable acquired resistance mechanisms. Subsequently, no objective response to osimertinib or afatinib rechallenge was observed. Acquired EGFR and MET amplification were detected in corresponding rebiopsies. Overall survival was 29 months. Our findings suggest that, despite the presence of the previously reported EGFR-TKI-sensitive, EGFR p.S752_I759del, the co-occurrence of germline p.V843I may have contributed to reduced sensitivity to afatinib and osimertinib. This case expands the molecular spectrum of hereditary EGFR-mutated NSCLC and, together with our narrative review of the literature, supports an emerging model in which germline EGFR PVs may act both as tumor-predisposing events and as potential mechanisms of early resistance to EGFR-TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen, Denmark.
- Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
ORCID-Profile: Jens Benn Sørensen, Karin Anna Wallentin Wadt, Edyta Maria Urbanska, Eric Santoni-Rugiu
Zitieren
APA
Resen, K., Melchior, L. C., Sørensen, J. B., Wadt, K. A. W., Urbanska, E. M., & Santoni-Rugiu, E. (2026). Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs. International Journal of Molecular Sciences, 27(16), 7260. https://doi.org/10.3390/ijms27167260
Vancouver
Resen K, Melchior LC, Sørensen JB, Wadt KAW, Urbanska EM, Santoni-Rugiu E. Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs. International Journal of Molecular Sciences. 2026;27(16):7260. doi:10.3390/ijms27167260
BibTeX
@article{Resen2026,
author = {Resen, Katarina and Melchior, Linea Cecilie and Sørensen, Jens Benn and Wadt, Karin Anna Wallentin and Urbanska, Edyta Maria and Santoni-Rugiu, Eric},
title = {Novel Co-Occurrence of Germline EGFR p.V843I and Somatic EGFR Exon 19 Deletion in NSCLC: Insights into Reduced Sensitivity to EGFR-TKIs},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {16},
pages = {7260},
doi = {10.3390/ijms27167260}
}
EUVIMED